EY has announced the launch of EY Smart Reviewer, a technology-driven solution that leverages artificial intelligence (AI) and natural language processing to help accelerate and improve the process to review materials used to market pharmaceutical and medical device products.
”The industry's current Medical, Legal, Regulatory Review (MLR) process, which helps to ensure marketing materials comply with regulatory guidelines, is often slow, inconsistent and requires significant manual review times for documents. There are also significant risks if off-label or other non-compliant messaging are hastily approved. Non-compliance with regulations can result in millions of dollars in regulatory fines, as well as delay actively promoting essential new therapies in the market.
The EY Smart Reviewer solution “makes it possible for pharmaceutical and medical technology companies to automate the Medical, Legal, Regulatory Review (MLR) process and significantly shorten review and approval timelines for modular content, thus driving faster speed to market for essential medicines,” said EY in a press release. “It increases speed by eliminating key manual tasks and automating the remaining tasks and it reduces costs by freeing up high-value people to focus on higher value-adding omnichannel activities, while lowering risk of regulatory fines.” I
Twelve machine learning modules make up the solution, with new modules being developed and added over time. Currently available in English, EY Smart Reviewer will also be available in French, German, Spanish, Italian, Japanese and Chinese by early 2022.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.